Clinical Trial Update: Efficacy and Safety of Intranasal MSP-2017 (Etripamil) for the Conversion of PSVT to Sinus Rhythm [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating intranasal MSP-2017 (etripamil) for converting paroxysmal supraventricular tachycardia to sinus rhythm; study completed with results po…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Paroxysmal Supraventricular Tachycardia

Drugs mentioned

• MSP-2017 (etripamil) (etripamil)

Snippet

Sponsor: Milestone Pharmaceuticals Inc. | Conditions: Paroxysmal Supraventricular Tachycardia (PSVT) | Phase 2 | Status: COMPLETED | Results posted: 2020-12-30